List view / Grid view
14 April 2016 | By Victoria White, Digital Content Producer
Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV...
13 April 2016 | By Victoria White, Digital Content Producer
A study has shown that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens...
26 February 2016 | By Victoria White
The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study...
26 February 2016 | By Victoria White
TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread at one-tenth of the dose...
24 February 2016 | By Victoria White
GlobalData says China will continue to dominate the hepatitis B treatment space, as its market share rises from 38.8% in 2014 to 47.2% by 2024...
15 February 2016 | By Victoria White
A GlobalData analyst says that the combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake...
8 February 2016 | By Victoria White
The expanded label for Daklinza includes three additional patient populations: HCV patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV...
29 January 2016 | By Victoria White
Zepatier is a once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir...
29 January 2016 | By Victoria White
The expanded label allows for the use of Daklinza (daclatasvir) in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV...
20 January 2016 | By Victoria White
GlobalData says the expansion will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease...
13 January 2016 | By Victoria White
IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus...
11 January 2016 | By Victoria White
AbbVie's investigational HCV regimen, combining ABT-493 and ABT-530, will be evaluated in patients with genotypes 1-6 chronic HCV infection...
6 January 2016 | By Victoria White
The studies demonstrated that TAF was non-inferior to Gilead’s Viread (tenofovir disoproxil fumarate, TDF) based on the percentage of patients with HBV DNA levels below 29 IU/mL at 48 weeks of therapy...
16 November 2015 | By Victoria White
The data show high rates of sustained virologic response at 12 weeks post-treatment in non-cirrhotic patients with chronic hepatitis C virus infection...
16 November 2015 | By Victoria White
Results announced show that 95% of patients achieved a sustained virologic response at 12 weeks post-treatment...
